Table 1. Cohort characteristics.
*Unknown due to surgery being performed at an outside institution. +Timeline was after initial or reirradiation treatment was completed until death
CI: confidence interval; CNS: central nervous system; ECOG: Eastern Cooperative Oncology Group; IDH: isocitrate dehydrogenase; IQR: interquartile range; MGMT: O6-methylguanine-DNA methyltransferase; RT: radiotherapy
| Characteristics | |
| Number of patients | 13 |
| Sex, n (%) | |
| Male | 11 (84.6%) |
| Female | 2 (15.4%) |
| Age at diagnosis, years, n (%) | |
| 30-39 | 1 (7.7%) |
| 40-49 | 3 (23.1%) |
| 50-59 | 4 (30.8%) |
| 60-69 | 4 (30.8%) |
| 70-79 | 1 (7.7%) |
| Race, n (%) | |
| White | 6 (46.2%) |
| Black or African American | 5 (38.5%) |
| Other | 2 (15.4%) |
| Ethnicity, n (%) | |
| Hispanic, Latino/a, or Spanish origin | 4 (30.8%) |
| Not of Hispanic, Latino/a, or Spanish origin | 9 (69.2%) |
| Performance status, n (%) | |
| ECOG 0 | 2 (15.4%) |
| ECOG 1 | 7 (53.8%) |
| ECOG 2 | 4 (30.8%) |
| MGMT methylation status, n (%) | |
| MGMT methylated | 6 (46.2%) |
| MGMT unmethylated | 4 (30.8%) |
| MGMT unknown | 3 (23.1%) |
| IDH mutation status, n (%) | |
| IDH wildtype | 10 (76.9%) |
| IDH mutant | 1 (7.7%) |
| IDH unknown | 2 (15.4%) |
| Initial radiation treatment, n (%) | |
| 60 Gy in 30 fx | 7 (53.8%) |
| 54 Gy in 27 fx | 3 (15.4%) |
| 40.05 Gy in 15 fx | 1 (7.7%) |
| 35 Gy in 10 fx | 1 (7.7%) |
| 30 Gy in 10 fx | 1 (7.7%) |
| Received temozolomide with initial RT, n (%) | |
| Yes | 13 (100%) |
| No | 0 (0.0%) |
| Weeks between initial surgery and the start of RT, n (%) | |
| 01-Feb | 1 (7.7%) |
| 02-Jun | 6 (46.2%) |
| 06-Oct | 5 (38.5%) |
| Unknown* | 1 (7.7%) |
| Course one toxicity, n (%) | |
| No acute toxicity | 7 (53.8%) |
| One or more acute grade 1 toxicities | 6 (46.2%) |
| Grade 1 skin toxicity | 5 (38.5%) |
| Grade 1 CNS toxicity | 2 (15.4%) |
| Initial surgery, n (%) | |
| Gross total resection | 4 (30.8%) |
| Subtotal resection | 7 (53.8%) |
| Stereotactic biopsy only | 1 (7.7%) |
| Unknown* | 1 (7.7%) |
| Systemic therapies, n (%) | |
| Temozolomide only | 1 (7.7%) |
| Temozolomide and bevacizumab only | 7 (53.8%) |
| Temozolomide and bevacizumab plus evolizumab | 1 (7.7%) |
| Temozolomide and bevacizumab plus lomustine only | 2 (15.4%) |
| Temozolomide and bevacizumab plus lomustine and etoposide | 1 (7.7%) |
| Temozolomide and bevacizumab plus lomustine and topotecan | 1 (7.7%) |
| Progression-free survival after initial RT, months, median (IQR) | 20.8 (6.5-60.1) |
| Overall survival after initial RT, months, median (IQR)+ | 38 (17-65) |
| Additional resections, n (%) | |
| Gross total resection | 5 (38.5%) |
| Subtotal resection | 3 (23.1%) |
| None | 5 (38.5%) |
| Reirradiation dose, n (%) | |
| 12 Gy in 1 fx | 1 (7.7%) |
| 25 Gy in 5 fx | 2 (15.4%) |
| 30 Gy in 10 fx | 1 (7.7%) |
| 35 Gy in 10 fx | 7 (53.8%) |
| 40 Gy in 15 fx | 1 (7.7%) |
| Reirradiation course toxicity, n (%) | |
| No acute toxicity | 12 (92.3%) |
| Grade 1 skin toxicity | 1 (7.7%) |
| Progression-free survival after irradiation, months, median (95% CI) | 3 (1-4) |
| Overall survival after irradiation, months, median (95% CI)+ | 5 (1-8) |
| Tumor-treating fields used, n (%) | |
| Yes | 3 (23.1%) |
| No | 11 (84.6%) |
| Time to last follow-up from the end of reirradiation, weeks, median (IQR) | 22.5 (9-35.8) |